Advances and Challenges in Understanding Cerebral Toxoplasmosis

Drugs in development for toxoplasmosis: advances, challenges, and current status

Toxoplasma gondii causes fatal and debilitating brain and eye diseases. Medicines that are currently used to treat toxoplasmosis commonly have toxic side effects and require prolonged courses that range from weeks to more than a year. The need for long treatment durations and the risk of relapsing disease are in part due to the lack of efficacy against T. gondii tissue cysts. The challenges for...

Advances and challenges in recombinant protein expression in Escherichia coli

Toxoplasmosis: Advances and Vaccine Perspectives

Toxoplasma gondii was first identified more than 100 years ago in the tissues of birds and mammals. In 1908 Nicolle and Manceoux described it for the first time in the gundi (Ctenodactylus gundi), a North African rodent, in tachyzoite forms. At the same time, Splendore in Brazil, identified the parasite in rabbit tissues. Due to its bow-like shape (Greek: Toxo = Arc) the genus was named Toxopla...

Editorial: Current advances and challenges in understanding plant desiccation tolerance

Citation: Moore JP and Farrant JM (2015) Editorial: Current advances and challenges in understanding plant desiccation tolerance. One of the most exciting and gratifying privileges of having edited this research topic on plant desiccation tolerance is that we received papers and reviews on resurrection plant species (particularly angiosperms) covering five continents, almost six, although unfor...

Immunopathogenesis of cerebral toxoplasmosis.

Interferon (IFN)-gamma is an absolute requirement for resistance against acute acquired infection with Toxoplasma gondii and development of toxoplasmic encephalitis (TE) during the late stage of infection. Multiple populations of both T and non-T cells are important sources of IFN-gamma in resistance. In the absence of IFN-gamma-producing non-T cells, T cells cannot prevent TE. Interleukin-12, ...